FDA-Approved Bipolar Medications: Comprehensive List with Specifiers
All FDA-approved medications for bipolar disorder are listed below, organized by indication with their specific dosing parameters and approved uses.
Acute Mania/Mixed Episodes
First-Generation Antipsychotics
- Haloperidol: Effective for acute mania with moderate-to-high certainty evidence 1
Second-Generation Antipsychotics (Monotherapy)
- Aripiprazole: FDA-approved for acute mania/mixed episodes; also approved for maintenance 2, 1
- Asenapine: FDA-approved for acute mania/mixed episodes 1, 2
- Cariprazine: FDA-approved for acute mania/mixed episodes with high certainty evidence 1
- Olanzapine: FDA-approved for acute mania/mixed episodes; also approved for maintenance 2, 1
- Quetiapine: FDA-approved for acute mania/mixed episodes (immediate and extended-release formulations) 2, 3
- Risperidone: FDA-approved for acute mania/mixed episodes 2, 1
- Ziprasidone: FDA-approved for acute mania/mixed episodes 2, 1
- Paliperidone: FDA-approved for acute mania/mixed episodes 1
Mood Stabilizers
- Lithium: FDA-approved for acute mania and maintenance; high certainty evidence across outcomes 1, 2
- Divalproex/Valproate: FDA-approved for acute mania 1, 2
- Carbamazepine: FDA-approved for acute mania 1, 2
Bipolar Depression
Monotherapy Options
- Quetiapine: FDA-approved as monotherapy for bipolar depression (both immediate-release and extended-release formulations) 3, 4, 5
- Lurasidone: FDA-approved as monotherapy for bipolar depression 3, 4, 5
Combination Therapy
- Olanzapine-Fluoxetine Combination (OFC): FDA-approved specifically for bipolar depression 3, 4, 5, 2
- Lurasidone: Also FDA-approved as adjunct to lithium or valproate for bipolar depression 3, 5
Maintenance Treatment
Only two medications have FDA approval specifically for maintenance therapy based on randomized controlled trials 2:
- Olanzapine: FDA-approved for maintenance monotherapy
- Aripiprazole: FDA-approved for maintenance monotherapy
Lamotrigine: While not FDA-approved for acute treatment, it has compelling evidence for maintenance therapy, particularly as adjunct to lithium and for prevention of depressive episodes 1, 5
Pediatric Indications (Children and Adolescents)
For Mania
- Aripiprazole: High certainty evidence 1
- Asenapine: High certainty evidence 1
- Olanzapine: High certainty evidence 1
- Quetiapine: High certainty evidence 1
- Risperidone: High certainty evidence 1
For Bipolar Depression
- Olanzapine-Fluoxetine Combination: Moderate certainty evidence 1
- Lurasidone: Moderate certainty evidence 1
Key Clinical Considerations
Efficacy profiles: The NNT (number needed to treat) for response ranges from 4-7 and for remission 5-7 across the three FDA-approved bipolar depression treatments, indicating similar efficacy 4.
Tolerability differences are critical for selection 4:
- OFC: NNH of 6 for ≥7% weight gain
- Quetiapine: NNH of 16 for ≥7% weight gain; NNH of 3 for somnolence
- Lurasidone monotherapy: NNH of 58 for ≥7% weight gain (most metabolically favorable)
Common pitfall: None of the classic antidepressants (SSRIs, SNRIs) have FDA approval as monotherapy for bipolar depression—using them alone represents incorrect treatment 4.